A new trial targets patients with advanced solid tumors, including pancreatic cancer, with an MTAP-deletion genetic mutation.
Dr. Tanios Bekaii-Saab reports promising results of the KRYSTAL-1 trial, which targets a KRAS mutation common to pancreatic cancer.
Dr. Kim A. Reiss is leading a study of the PARP inhibitor olaparib to delay or prevent a recurrence of surgically removed pancreatic cancer.
Chris Treubert started with one type of chemotherapy but when the results of genetic testing showed a BRCA mutation he changed treatment.
Dr. Angela Bradbury is leading a study on access to genetic testing and genetic counseling, including a telehealth option.
Gina Harrison underwent molecular profiling of her pancreatic tumor, which led her to a clinical trial. Genetic testing showed her BRCA1 mutation was random.
Beverly Leighton joined a screening study and underwent genetic testing because of her family history of pancreatic cancer.
Dr. Manish Shah leads a clinical trial of high-dose vitamin C targeting KRAS and BRAF mutations in solid-tumor cancers, including pancreatic cancer.
Harvey Parker had genetic testing as part of his initial pancreatic cancer treatment. The BRCA2 mutation led him to a PARP inhibitor clinical trial.